[go: up one dir, main page]

AU2001274236A1 - Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist - Google Patents

Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist

Info

Publication number
AU2001274236A1
AU2001274236A1 AU2001274236A AU7423601A AU2001274236A1 AU 2001274236 A1 AU2001274236 A1 AU 2001274236A1 AU 2001274236 A AU2001274236 A AU 2001274236A AU 7423601 A AU7423601 A AU 7423601A AU 2001274236 A1 AU2001274236 A1 AU 2001274236A1
Authority
AU
Australia
Prior art keywords
intergrinantagonist
alpha4
inhalation
dry
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274236A
Inventor
Duncan Robert Armour
David Brown
Miles Stuart Congreve
Paul Martin Gore
Darren Victor Steven Green
Stuart Holman
Torquil Iain Maclean Jack
Steven Philip Keeling
Andrew Mcmurtrie Mason
Karen Morriss
Nigel Grahame Ramsden
Marian Thomas
Peter Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001274236A1 publication Critical patent/AU2001274236A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001274236A 2000-06-16 2001-06-15 Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist Abandoned AU2001274236A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014851 2000-06-16
GBGB0014851.0A GB0014851D0 (en) 2000-06-16 2000-06-16 Novel pharmaceutical formulation
PCT/GB2001/002656 WO2001095885A1 (en) 2000-06-16 2001-06-15 Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrin antagonist

Publications (1)

Publication Number Publication Date
AU2001274236A1 true AU2001274236A1 (en) 2001-12-24

Family

ID=9893864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274236A Abandoned AU2001274236A1 (en) 2000-06-16 2001-06-15 Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist

Country Status (6)

Country Link
US (1) US20040037784A1 (en)
EP (1) EP1292286A1 (en)
JP (1) JP2004503492A (en)
AU (1) AU2001274236A1 (en)
GB (1) GB0014851D0 (en)
WO (1) WO2001095885A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338402A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried, amorphous BIBN 4096, process for its preparation and its use as inhalant
DE10338399A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder
EP3199164B1 (en) * 2005-02-10 2020-03-18 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2012058719A1 (en) * 2010-11-02 2012-05-10 The Universtity Of Sydney Inhalable compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB9924415D0 (en) * 1999-10-16 1999-12-15 Glaxo Group Ltd Medicament pack

Also Published As

Publication number Publication date
WO2001095885A1 (en) 2001-12-20
GB0014851D0 (en) 2000-08-09
JP2004503492A (en) 2004-02-05
EP1292286A1 (en) 2003-03-19
US20040037784A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2002234476A1 (en) Medical aerosol formulations
GB0102342D0 (en) Pharmaceutical formulation
AU2002223028A1 (en) Inhaler
AU2002257582A1 (en) Pharmaceutical formulation
AU1986099A (en) Device for inhaling medicament
AU4803500A (en) Aerosol inhalation device providing improved aerosol delivery
AU2001258550A1 (en) Insulin formulation for inhalation
AU2001248943A1 (en) Pharmaceutical curative compound
AU2003238039A1 (en) Nasal peptide pharmaceutical formulation
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2001232017A1 (en) Pharmaceutical composition for pulmonary delivery
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU1141101A (en) Pharmaceutical aerosol formulations comprising s-salmeterol
AU2002361850A1 (en) Medicinal aerosol formulations comprising ion pair complexes
AU2001274236A1 (en) Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist
AU2001260281A1 (en) Medicament for combating respiratory depression
AU6028101A (en) Medicament for combating respiratory depression
AU2002238748A1 (en) Pharmaceutical aerosol formulation
GB0014849D0 (en) Pharmaceutical aerosol formulation
AU2001287930A1 (en) Pharmaceutical formulation for pulmonary or nasal administration
AU2001230490A1 (en) Pharmaceutical formulation
GB0014881D0 (en) Pharmaceutical aerosol formulation
GB0106018D0 (en) Pharmaceutical aerosol formulation
GB0128335D0 (en) Pharmaceutical aerosol formulation